160 related articles for article (PubMed ID: 34995453)
21. Aiming at Ideal Therapeutics-MOPr/DOPr or MOPr-DOPr Heteromertargeting Ligand.
Fujita W
Curr Top Med Chem; 2020; 20(31):2843-2851. PubMed ID: 32324516
[TBL] [Abstract][Full Text] [Related]
22. Relative analgesic potency of mu, delta and kappa opioids after spinal administration in amphibians.
Stevens CW
J Pharmacol Exp Ther; 1996 Feb; 276(2):440-8. PubMed ID: 8632308
[TBL] [Abstract][Full Text] [Related]
23. Biased versus Partial Agonism in the Search for Safer Opioid Analgesics.
Azevedo Neto J; Costanzini A; De Giorgio R; Lambert DG; Ruzza C; Calò G
Molecules; 2020 Aug; 25(17):. PubMed ID: 32854452
[TBL] [Abstract][Full Text] [Related]
24. Progress in the development of more effective and safer analgesics for pain management.
Turnaturi R; Chiechio S; Salerno L; Rescifina A; Pittalà V; Cantarella G; Tomarchio E; Parenti C; Pasquinucci L
Eur J Med Chem; 2019 Dec; 183():111701. PubMed ID: 31550662
[TBL] [Abstract][Full Text] [Related]
25. Dextromethorphan and ketamine potentiate the antinociceptive effects of mu- but not delta- or kappa-opioid agonists in a mouse model of acute pain.
Baker AK; Hoffmann VL; Meert TF
Pharmacol Biochem Behav; 2002 Dec; 74(1):73-86. PubMed ID: 12376154
[TBL] [Abstract][Full Text] [Related]
26. New concepts in opioid analgesia.
Stein C
Expert Opin Investig Drugs; 2018 Oct; 27(10):765-775. PubMed ID: 30148648
[TBL] [Abstract][Full Text] [Related]
27. A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates.
Ding H; Kiguchi N; Yasuda D; Daga PR; Polgar WE; Lu JJ; Czoty PW; Kishioka S; Zaveri NT; Ko MC
Sci Transl Med; 2018 Aug; 10(456):. PubMed ID: 30158150
[TBL] [Abstract][Full Text] [Related]
28. [The mu, delta and kappa properties of various opioids].
Ohta S; Niwa M; Nozaki M; Hattori M; Shimonaka H; Dohi S
Masui; 1995 Sep; 44(9):1228-32. PubMed ID: 8523655
[TBL] [Abstract][Full Text] [Related]
29. From Plant to Chemistry: Sources of Active Opioid Antinociceptive Principles for Medicinal Chemistry and Drug Design.
Turnaturi R; Piana S; Spoto S; Costanzo G; Reina L; Pasquinucci L; Parenti C
Molecules; 2023 Oct; 28(20):. PubMed ID: 37894567
[TBL] [Abstract][Full Text] [Related]
30. APOLLO-2: A Randomized, Placebo and Active-Controlled Phase III Study Investigating Oliceridine (TRV130), a G Protein-Biased Ligand at the μ-Opioid Receptor, for Management of Moderate to Severe Acute Pain Following Abdominoplasty.
Singla NK; Skobieranda F; Soergel DG; Salamea M; Burt DA; Demitrack MA; Viscusi ER
Pain Pract; 2019 Sep; 19(7):715-731. PubMed ID: 31162798
[TBL] [Abstract][Full Text] [Related]
31. Investigational peptide and peptidomimetic μ and δ opioid receptor agonists in the relief of pain.
Giri AK; Hruby VJ
Expert Opin Investig Drugs; 2014 Feb; 23(2):227-41. PubMed ID: 24329035
[TBL] [Abstract][Full Text] [Related]
32. A comparison of the antinociceptive and adverse effects of the mu-opioid agonist morphine and the delta-opioid agonist SNC80.
Gallantine EL; Meert TF
Basic Clin Pharmacol Toxicol; 2005 Jul; 97(1):39-51. PubMed ID: 15943758
[TBL] [Abstract][Full Text] [Related]
33. Antinociceptive effects of the 6-O-sulfate ester of morphine in normal and diabetic rats: Comparative role of mu- and delta-opioid receptors.
Yadlapalli JSK; Ford BM; Ketkar A; Wan A; Penthala NR; Eoff RL; Prather PL; Dobretsov M; Crooks PA
Pharmacol Res; 2016 Nov; 113(Pt A):335-347. PubMed ID: 27637375
[TBL] [Abstract][Full Text] [Related]
34. Targeting multiple opioid receptors - improved analgesics with reduced side effects?
Günther T; Dasgupta P; Mann A; Miess E; Kliewer A; Fritzwanker S; Steinborn R; Schulz S
Br J Pharmacol; 2018 Jul; 175(14):2857-2868. PubMed ID: 28378462
[TBL] [Abstract][Full Text] [Related]
35. A bifunctional-biased mu-opioid agonist-neuropeptide FF receptor antagonist as analgesic with improved acute and chronic side effects.
Drieu la Rochelle A; Guillemyn K; Dumitrascuta M; Martin C; Utard V; Quillet R; Schneider S; Daubeuf F; Willemse T; Mampuys P; Maes BUW; Frossard N; Bihel F; Spetea M; Simonin F; Ballet S
Pain; 2018 Sep; 159(9):1705-1718. PubMed ID: 29708942
[TBL] [Abstract][Full Text] [Related]
36. Responsible prescribing of opioids for the management of chronic pain.
Nicholson B
Drugs; 2003; 63(1):17-32. PubMed ID: 12487620
[TBL] [Abstract][Full Text] [Related]
37. Characterization of a Potential KOR/DOR Dual Agonist with No Apparent Abuse Liability via a Complementary Structure-Activity Relationship Study on Nalfurafine Analogues.
Li M; Stevens DL; Arriaga M; Townsend EA; Mendez RE; Blajkevch NA; Selley DE; Banks ML; Negus SS; Dewey WL; Zhang Y
ACS Chem Neurosci; 2022 Dec; 13(24):3608-3628. PubMed ID: 36449691
[TBL] [Abstract][Full Text] [Related]
38. The Abuse Potential of Prescription Opioids in Humans-Closing in on the First Century of Research.
Walsh SL; Babalonis S
Curr Top Behav Neurosci; 2017; 34():33-58. PubMed ID: 27356522
[TBL] [Abstract][Full Text] [Related]
39. Multivalent peptide and peptidomimetic ligands for the treatment of pain without toxicities and addiction.
Hruby VJ
Peptides; 2019 Jun; 116():63-67. PubMed ID: 31014958
[TBL] [Abstract][Full Text] [Related]
40. From Plant to Chemistry: Sources of Antinociceptive Non-Opioid Active Principles for Medicinal Chemistry and Drug Design.
Turnaturi R; Piana S; Spoto S; Costanzo G; Reina L; Pasquinucci L; Parenti C
Molecules; 2024 Feb; 29(4):. PubMed ID: 38398566
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
